Details of the Drug Combinations

General Information of This Drug (ID: DMJWRQP)

Drug Name

Zanubrutinib DMJWRQP

Synonyms

RNOAOAWBMHREKO-UHFFFAOYSA-N; 1633350-06-7; ( inverted exclamation markA)-Zanubrutinib; CHEMBL3973435; SCHEMBL19742851; SCHEMBL16208602; BGB3111; BDBM249900; BCP29110; BCP25045; BCP25838; AKOS032946689; SB18877; CS-6366; ( inverted exclamation markA)-BGB-3111; HY-101474; US9447106, 27

Indication

Disease Entry	ICD 11	Status	REF
Mantle cell lymphoma	2A85.5	Approved	[1]
Chronic lymphocytic leukaemia	2A82.0	Phase 3	[2]
Small lymphocytic lymphoma	2A82.0	Phase 3	[2]
Waldenstrom macroglobulinemia	2A85.4	Phase 3	[2]
B-cell lymphoma	2A86	Phase 1	[2]
------------------------------------------------------------------------------------

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

1 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Zanubrutinib + Marizomib	DCZ4HDN	Marizomib	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[3]
------------------------------------------------------------------------------------

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.